GlassScriptPhysician profile
Joseph T Dodd
NPI 1053314195
$2,843.45
in general payments reported to CMS, 2019-2025
28 companies · $291 in 2025
The $291 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166 · 2020: $14.35 · 2021: $134 · 2022: $287 · 2023: $247 · 2024: $1,704 · 2025: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,824 · Travel and Lodging: $417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,824.47 |
| Travel and Lodging | $417.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $1,270.40 | 2024 | |
| Organogenesis INC. | $181.89 | 2019-2023 | Puraply |
| Abbvie INC. | $179.26 | 2022-2023 | Dalvance, Teflaro |
| Boston Scientific Corporation | $158.25 | 2025 | General - Therapies |
| Medtronic, INC. | $153.08 | 2024 | Signia |
| Davol INC. | $149.37 | 2024 | Phasix Mesh |
| Melinta Therapeutics, LLC | $137.12 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $96.73 | 2023-2025 | Vaxneuvance, Gardasil 9, Gardasil |
| Phathom Pharmaceuticals, INC. | $68.41 | 2024-2025 | Voquezna |
| Actelion Pharmaceuticals US, INC. | $49.24 | 2021-2022 | |
| Harmony Biosciences LLC | $45.43 | 2021-2022 | |
| Grifols USA, LLC | $37.36 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.88 | 2022-2024 | Gattex |
| Genzyme Corporation | $26.44 | 2025 | |
| Endogastric Solutions, INC | $26.23 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hydrofera LLC | $24.42 | 2025 | Hydrofera Blue |
| Btg International INC. | $23.89 | 2019 | |
| Coloplast Corp | $22.33 | 2024 | |
| Sanofi Pasteur INC. | $19.22 | 2022 | |
| Pacira Therapeutics, INC. | $18.25 | 2019 | |
| Cook Medical LLC | $18.20 | 2019 | |
| Pfizer INC. | $18.09 | 2019 | |
| Reapplix INC. | $16.65 | 2021 | |
| Braintree Laboratories, INC. | $15.75 | 2025 | Suflave, Sutab |
| Vertex Pharmaceuticals Incorporated | $15.35 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $14.07 | 2024 | Andexxa |
| Next Science LLC | $13.67 | 2024 | Blastx, Xperience, Surgx |
| Exeltis, USA INC. | $11.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Dodd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.